Compugen (NASDAQ:CGEN) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket.
Incyte (NASDAQ:INCY) resumed with Outperform rating at William Blair. Shares up 3% premarket.
NextCure (NASDAQ:NXTC) initiated with Buy rating and $55 (70% upside) price target at Benchmark.
Passage Bio (NASDAQ:PASG)
initiated with Buy rating and $27 (124% upside) price target at Goldman
Sachs, Outperform at Cowen and Company and Buy with a $25 price target
at JPMorgan.
Verrica Pharmaceuticals (NASDAQ:VRCA) initiated with Buy rating and $20 (150% upside) price target at Needham.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) upgraded to Market Perform at SVB Leerink.
CytomX Therapeutics (NASDAQ:CTMX) upgraded to Outperform with a $10 (103% upside) price target at Wedbush. Shares up 33% premarket on Astellas collaboration in cancer.
Perrigo (NYSE:PRGO) upgraded to Overweight with a $57 (35% upside) price target at JPMorgan. Shares up 8% premarket.
Ligand Pharmaceuticals (NASDAQ:LGND) downgraded to Hold at Argus.
Milestone Pharmaceuticals (NASDAQ:MIST) downgraded to Neutral at Piper Sandler and Market Perform at Oppenheimer. Shares down 75% premarket on failed etripamil study.
https://seekingalpha.com/news/3554598-blair-likes-incyte-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.